Since EREG-mediated stabilization of PDL1 is critical for immune evasion in HNSCC, next we asked whether targeting EREG glycosylation via NGI-1 would enhance the antitumor efficacy of PDL1/PD-1 blockade therapy in vivo. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.